ERBB2 and breast cancer: Despite great advances in the systemic treatment of BC over recent years, largely attributable to the rise of endocrine therapy, anti-HER2 therapy, CDK4/6 inhibitor, and mTOR inhibitor (2), tumor progression and distant metastasis (DM) remain the major obstacles for the long-term survival of BC patients (3).